Sugi Predict

Sugi Predict / Compounds / SCHEMBL30910345

SCHEMBL30910345

SCHEMBL30910345

COCOc1cc(-c2nc(OC)c3c(N4CC5CCC(C4)N5C(=O)OC(C)(C)C)nc(S(C)(=O)=O)nc3c2F)c2c(C#C[Si](C(C)C)(C(C)C)C(C)C)c(F)ccc2c1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 5/20 0.36
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30910344 1.00 GPR119 (0.36) GPR119JAK2JAK1TYK2JAK3
SCHEMBL31049020 0.92 JAK2 (0.33) GPR119JAK2JAK1TYK2JAK3
SCHEMBL31049240 0.91 JAK2 (0.33) GPR119JAK2JAK1TYK2JAK3
SCHEMBL30149131 0.91 GPR119 (0.36) GPR119JAK2JAK1TYK2JAK3
SCHEMBL30149022 0.91 GPR119 (0.36) GPR119JAK2JAK1TYK2JAK3
SCHEMBL25437918 0.91 GPR119 (0.36) GPR119JAK2JAK1TYK2JAK3
SCHEMBL31048952 0.90 JAK2 (0.32) GPR119JAK2JAK1TYK2JAK3
SCHEMBL31712546 0.87 — —
SCHEMBL31049023 0.87 JAK2 (0.33) GPR119JAK2JAK1TYK2JAK3
SCHEMBL31049113 0.87 JAK2 (0.33) GPR119JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626895-A1 4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF THE KRAS(G12D) MUTANT ONCOPROTEIN FOR THE TREATMENT OF CANCER Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) 2025-10-08 — — EP disclosed
WO-2024118926-A1 4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF THE KRAS(G12D) MUTANT ONCOPROTEIN FOR THE TREATMENT OF CANCER RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) 2024-06-06 — — WO disclosed